Literature DB >> 15486192

Peroxisome proliferator-activated receptor gamma and retinoid X receptor ligands are potent inducers of differentiation and apoptosis in leukemias.

Marina Konopleva1, Elena Elstner, Teresa J McQueen, Twee Tsao, Andrey Sudarikov, Wei Hu, Wendy D Schober, Rui-Yu Wang, David Chism, Steven M Kornblau, Anas Younes, Steven J Collins, H Phillip Koeffler, Michael Andreeff.   

Abstract

The peroxisome proliferator-activated receptor gamma (PPAR gamma) is a member of the nuclear receptor family that forms heterodimers with retinoid X receptor. These heterodimers bind to DNA and activate the transcription of target genes. Here, we report that the PPAR gamma receptor protein is expressed in primary myeloid and lymphoid leukemias and in lymphoma and myeloma cell lines. In this study, we compared the activity of several PPAR gamma ligands including BRL49653 (rosiglitazone), 15-deoxy-Delta 12,14-prostaglandin J(2), and the novel triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid on leukemia cells. Exposure to these PPAR gamma ligands induced apoptosis in myeloid (U937 and HL-60) and lymphoid (Su-DHL, Sup-M2, Ramos, Raji, Hodgkin's cell lines, and primary chronic lymphocytic leukemia) cells. A similar exposure to these PPAR gamma ligands induced the differentiation of myeloid leukemic cells. A combination of PPAR gamma ligands with a retinoid X receptor agonist (i.e., LG100268) or a retinoic acid receptor agonist (i.e., all trans-retinoic acid) enhanced differentiating and growth-inhibitory effects. 2-Cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced differentiation and apoptosis with much greater potency than the other PPAR gamma ligands in established cell lines and primary chronic lymphocytic leukemia samples. Exposure to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induced mitochondrial depolarization and caspase activation, which was associated with apoptosis induction. In Bcl-2-overexpressing chronic lymphocytic leukemia cells, the small-molecule Bcl-2 inhibitor HA14-1 sensitized these cells to 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid-induced apoptosis. These results suggest that PPAR gamma ligation alone and in combination with retinoids holds promise as novel therapy for leukemias by activating the transcriptional activity of target genes that control apoptosis and differentiation in leukemias.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486192

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  44 in total

1.  Role of peroxisome proliferator-activated receptor-gamma and its coactivator DRIP205 in cellular responses to CDDO (RTA-401) in acute myelogenous leukemia.

Authors:  Twee Tsao; Steven Kornblau; Stephen Safe; Julie C Watt; Vivian Ruvolo; Wenjing Chen; Yihua Qiu; Kevin R Coombes; Zhenlin Ju; Maen Abdelrahim; Wendy Schober; Xiaoyang Ling; Dimitris Kardassis; Colin Meyer; Aaron Schimmer; Hagop Kantarjian; Michael Andreeff; Marina Konopleva
Journal:  Cancer Res       Date:  2010-05-25       Impact factor: 12.701

2.  Activation of peroxisome proliferator-activated receptor gamma contributes to the survival of T lymphoma cells by affecting cellular metabolism.

Authors:  Chunyan Yang; Seung-Hee Jo; Balazs Csernus; Elizabeth Hyjek; Yifang Liu; Amy Chadburn; Y Lynn Wang
Journal:  Am J Pathol       Date:  2007-02       Impact factor: 4.307

Review 3.  Differentiation therapy of leukemia: 3 decades of development.

Authors:  Daniel Nowak; Daphne Stewart; H Phillip Koeffler
Journal:  Blood       Date:  2009-02-12       Impact factor: 22.113

4.  Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?

Authors:  Sevki Cetinkalp; Ilgın Yildirim Simsir; Fahri Sahin; Guray Saydam; Ali Ugur Ural; Candeger Yilmaz
Journal:  Saudi Pharm J       Date:  2013-12-22       Impact factor: 4.330

5.  Phosphorylation of Human Retinoid X Receptor α at Serine 260 Impairs Its Subcellular Localization, Receptor Interaction, Nuclear Mobility, and 1α,25-Dihydroxyvitamin D3-dependent DNA Binding in Ras-transformed Keratinocytes.

Authors:  Sylvester Jusu; John F Presley; Richard Kremer
Journal:  J Biol Chem       Date:  2016-11-16       Impact factor: 5.157

6.  Thiazolidinediones as anti-cancer agents.

Authors:  Carmelo Blanquicett; Jesse Roman; C Michael Hart
Journal:  Cancer Ther       Date:  2008

7.  Retinoid X receptor agonists inhibit phorbol-12-myristate-13-acetate (PMA)-induced differentiation of monocytic THP-1 cells into macrophages.

Authors:  Lei Zhou; Ling-Hong Shen; Liu-Hua Hu; Heng Ge; Jun Pu; Da-Jun Chai; Qin Shao; Li Wang; Jin-Zhang Zeng; Ben He
Journal:  Mol Cell Biochem       Date:  2009-09-27       Impact factor: 3.396

8.  Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

Authors:  P J Simpson-Haidaris; S J Pollock; S Ramon; N Guo; C F Woeller; S E Feldon; R P Phipps
Journal:  PPAR Res       Date:  2010-02-28       Impact factor: 4.964

9.  Peroxisome proliferator-activated receptor gamma overexpression suppresses growth and induces apoptosis in human multiple myeloma cells.

Authors:  Tatiana M Garcia-Bates; Steven H Bernstein; Richard P Phipps
Journal:  Clin Cancer Res       Date:  2008-10-15       Impact factor: 12.531

10.  CDX2-driven leukemogenesis involves KLF4 repression and deregulated PPARγ signaling.

Authors:  Katrin Faber; Lars Bullinger; Christine Ragu; Angela Garding; Daniel Mertens; Christina Miller; Daniela Martin; Daniel Walcher; Konstanze Döhner; Hartmut Döhner; Rainer Claus; Christoph Plass; Stephen M Sykes; Steven W Lane; Claudia Scholl; Stefan Fröhling
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.